Previous close | 0.1900 |
Open | 0.1700 |
Bid | 0.0000 |
Ask | 1.3500 |
Strike | 35.00 |
Expiry date | 2025-04-17 |
Day's range | 0.1700 - 0.1900 |
Contract range | N/A |
Volume | |
Open interest | 42 |
Organon (OGN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
JERSEY CITY, N.J., October 09, 2024--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.
SHANGHAI, China & JERSEY CITY, N.J., September 30, 2024--Henlius and Organon announce primary endpoint met in phase 3 comparative clinical study of Perjeta® (pertuzumab) biosimilar candidate HLX11